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0959-8049/ª 2016 Elsevier Ltd. All righAbstract Background: Sunitinib is an oral tyrosine kinase inhibitor used for cancer treat-
ment. Patients treated with sunitinib are at higher bleeding risk. As tyrosine kinases are essen-
tial for platelet signalling, the effects of sunitinib on platelet function in vitro and in cancer
patients on treatment were investigated.
Patients and methods: Blood samples were collected from eight healthy volunteers and eight
patients diagnosed with metastatic renal cell cancer (RCC) before and 2 weeks on treatment
with sunitinib. Platelets from 15 additional healthy individuals were preincubated with suniti-
nib or vehicle to perform in vitro experiments. Immunofluorescence imaging, western blotting,
light transmission aggregometry, whole blood perfusion over collagen, flow cytometry and
ELISA were performed.
Results: Confocal microscopy indicated that platelets sequester sunitinib in vitro and in pa-
tients. In platelets from healthy controls, tyrosine phosphorylation was inhibited by sunitinib.
Also, sunitinib dose dependently reduced collagen- and ADP-induced aggregation, collagen-
dependent thrombus formation and collagen-induced secretion of platelet-derived growth fac-
tor and b-thromboglobulin. In blood from RCC patients before treatment, thrombus forma-




S. Sabrkhany et al. / European Journal of Cancer 66 (2016) 47e5448After 14 d of sunitinib treatment, platelet count was moderately, but significantly decreased
(from 243 to 144  109/l). At the same time, collagen-induced platelet aggregation as well
as thrombus formation and phosphatidylserine exposure under flow were significantly reduced
(by 45%, 16% and 61%, respectively).
Conclusions: Sunitinib uptake by platelets inhibits collagen receptor-induced aggregation and
thrombus formation via reduction of protein tyrosine phosphorylation and a-granule secre-
tion. This dysfunction may contribute to the higher bleeding tendency observed in
sunitinib-treated patients.
ª 2016 Elsevier Ltd. All rights reserved.1. Introduction
Inhibition of protein tyrosine kinases has shown
considerable anticancer activity in patients with malig-
nancies [1]. The multitarget tyrosine kinase inhibitor
(TKI) sunitinib has been approved for the treatment of
advanced renal cell cancer (RCC) and for imatinib-
resistant gastrointestinal and pancreatic neuroendo-
crine tumours [2]. The effect of sunitinib in the man-
agement of several other malignancies is currently being
explored in several trials (ClinicalTrials.gov Identifiers:
NCT02074878, NCT01396148, NCT02058901 and
NCT00753727).
Although treatment with sunitinib has shown anti-
cancer effects and improves progression-free survival,
patients treated with this TKI may also encounter
bleeding. Overall, bleeding occurs in approximately 19%
of sunitinib-treated patients; about 3% of the bleeding
incidents are life threatening [3]. The mechanism un-
derlying this higher bleeding diathesis in patients treated
with sunitinib is still poorly understood. Haemostasis
upon vessel wall injury is an intricate process in which
platelets play a major role; it involves activation of
platelets by multiple exogenous and autocrine agonists
and their receptors [4]. Exposed extracellular matrix
proteins, including collagen and von Willebrand Factor
(vWF), first mediate platelet adhesion and activation, as
a prerequisite for ensuing aggregation and thrombus
formation. A subpopulation of activated platelets ex-
poses phosphatidylserine which promotes thrombin
generation and fibrin formation [5,6]. Platelets contain
multiple active protein tyrosine kinases [4] that are
essential for platelet functioning in haemostasis. More-
over, platelets also play an important role in tumour
angiogenesis and cancer progression [7]. The role of
platelets in sunitinib-induced toxicity has not been
explored.
The current study examined the hypothesis that
sunitinib treatment of cancer patients impairs platelet
haemostatic function, explaining the higher occurrence
of bleeding in patients undergoing this treatment. We
investigated the effects of sunitinib on platelet activa-
tion, aggregation and thrombus formation both in vitro
and in patients with RCC.2. Patients and methods
2.1. Patients
The study was approved by the medical ethics commit-
tee from Maastricht University Medical Centreþ
(MUMCþ, The Netherlands). Informed consent was
obtained from all participants in accordance with the
declaration of Helsinki. At the department of Medical
Oncology of MUMCþ, blood samples were obtained
from eight patients diagnosed with metastatic RCC and
eight healthy donors who were similar in age and gender
to the RCC patients. The patients included were treated
with sunitinib (Sutent, Pfizer, NYC, USA) as a single
agent. Subjects who used anticoagulants or platelet
inhibitory drugs or received chemotherapy were
excluded. One blood sample was collected from the
healthy donors; in the patient group, blood was sampled
two times: 1 d before and 14 d after starting sunitinib
treatment, i.e., within the first cycle of treatment. Blood
(10 ml) was collected from the antecubital vein in 3.2%
sodium citrate, and washed platelets were prepared as
described [8].
For all experiments in which the effects of sunitinib
on platelet functioning were measured in vitro, blood
samples from 15 additional healthy volunteers were
used. Before measurements, washed platelets or whole
blood from these healthy donors were preincubated with
sunitinib (3.33, 10 or 30 mM) or vehicle for 10 min at
37 C. Detailed information regarding used materials is
described in Supplementary materials.
2.2. Methods
Immunofluorescence imaging by confocal microscopy,
western blotting, light transmission aggregometry,
whole blood perfusion over collagen, flow cytometry
and ELISA were performed as described in
Supplementary methods.
2.3. Statistical analysis
Data were checked for Gaussian distribution using the
KolmogoroveSmirnov Normality test. Normally
S. Sabrkhany et al. / European Journal of Cancer 66 (2016) 47e54 49distributed data are presented as means  SEM; data
that are not normally distributed are presented as
median  interquartile ranges. GraphPad Prism 5.0
software was used for statistical analyses. Paired data
sets were compared using the Wilcoxon matched pairs
test, while unpaired samples were compared using the
ManneWhitney U test. A P-value less than 0.05 was
considered statistically significant.3. Results
3.1. Sunitinib is sequestered by platelets and inhibits
collagen-induced protein tyrosine phosphorylation
Visualisation by confocal microscopy of washed plate-
lets from healthy individuals that were treated with
10 mM sunitinib showed that platelets accumulate
sunitinib and sequester this fluorescent compound in
granules (Fig. 1A). This uptake of sunitinib from the
environment was observed within minutes after expo-
sure. Platelets contain several tyrosine kinases impli-
cated in platelet functioning, mostly acting in the
collagen-induced signalling pathway [4]. Western blot-
ting was used to investigate whether sunitinib affects
tyrosine phosphorylation of platelet proteins upon
collagen stimulation. Preincubation of washed platelets
with 10 mM sunitinib strongly reduced the tyrosineFig. 1. Sunitinib is sequestered by platelets and inhibits GPVI-induce
control platelets treated with 10 mM sunitinib (green) for 10 min. Pla
clustered localisation of sunitinib inside platelets (right image). Bar Z 1
experiments. (B) Representative western blot for four experiments with
with vehicle or sunitinib (10 or 30 mM) and stimulated with collagen (3
with 4G10 mAb. DIC Z differential interference contrast. (For interpre
referred to the web version of this article.).phosphorylation of multiple proteins induced by
collagen (Fig. 1B).3.2. Sunitinib inhibits collagen- and ADP-induced platelet
aggregation, thrombus formation and secretion in vitro
To investigate the effect of sunitinib on platelet func-
tioning, we first measured platelet aggregation induced
by different physiological agonists. Washed platelets
from healthy volunteers were treated for 10 min with
10 mM sunitinib. Platelet aggregation was induced with
thrombin, TRAP-6 (thrombin receptor activating pep-
tide 6, activating PAR-1), collagen, U46619 (throm-
boxane A2 analog), ADP and arachidonic acid. Only in
response to collagen and ADP, sunitinib inhibited
platelet aggregation (Supplementary Fig. 1). This
inhibiting effect of sunitinib on platelet aggregation
appeared to be dose dependent. While the maximal ag-
gregation response to either agonist was already signif-
icantly inhibited by 10 mM sunitinib, this response was
almost completely prevented by 30 mM (Fig. 2A,B).
Subsequently, we determined the effect of sunitinib
on collagen-induced thrombus formation at high (arte-
rial) wall shear rates. In whole blood perfusion experi-
ments, preincubation of blood with 10 mM sunitinib
slightly but significantly reduced thrombus formation on
collagen by 14% (Fig. 2C). With a higher sunitinib dosed protein tyrosine phosphorylation. (A) Confocal microscopy of
telet membranes were stained with anti-CD42b mAb (red). Note
0 mm, insert is 2.5 digital magnification. Representative for three
washed platelets from two healthy controls, incubated for 10 min
0 mg/ml) for 90 s. Protein tyrosine phosphorylation was visualised
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Fig. 2. Sunitinib inhibits collagen and ADP-induced platelet aggregation, thrombus formation and secretion in vitro. Whole blood or
washed platelets (250  109/l) from healthy donors were incubated with 3.3, 10 or 30 mM sunitinib or vehicle (0.1% DMSO) for 10 min. (A
and B): Representative aggregation curves and doseeresponse graphs (n Z 8) of inhibition of aggregation. Arrow indicates addition of
agonist. Aggregation of washed platelets was stimulated with 1 mg/ml collagen (A) or 10 nM Me-S-ADP (B). (C) Whole blood was
perfused over a collagen surface at 1000 s1 for 5 min, followed by buffer perfusion supplemented with FITC-annexin A5. Microscopy
images show representative brightfield and fluorescence images (Bar Z 20 mm). Histograms indicate quantification of surface area
coverage (SAC) by thrombi (n Z 5) and phosphatidylserine-exposing platelets (n Z 4). (D) Washed platelets were stimulated by collagen
(1 mg/ml), and releasates were collected; concentrations of b-thromboglobulin (b-TG) and PDGF were determined by ELISA (n Z 7). All
data are expressed as means  SEM, *P < 0.05 and **P < 0.01. PDGF Z platelet-derived growth factor; ELISA Z enzyme-linked
immunosorbent assay; ADP Z adenosine diphosphate; DMSO Z dimethyl sulfoxide; SEM Z standard error of the mean; FITC Z
fluorescein isothiocyanate.
S. Sabrkhany et al. / European Journal of Cancer 66 (2016) 47e5450(30 mM), thrombus formation was reduced further (by
24% as compared to vehicle, Fig. 2C). Treatment of
whole blood with sunitinib did not affect exposure of
phosphatidylserine (Fig. 2C).
To explore the effect of sunitinib on platelet secre-
tion, washed platelets were treated with 10 or 30 mM
sunitinib and activated with 1 mg/ml collagen. Secretion
of both b-thromboglobulin (b-TG) and platelet-derived
growth factor (PDGF) was significantly reduced by both
concentrations of sunitinib (Fig. 2D).
3.3. Treatment with sunitinib inhibits collagen-induced
platelet function in RCC patients
To investigate the clinical significance of inhibition of
platelet functioning by sunitinib, eight patients diag-
nosed with metastatic RCC and eligible for sunitinibtreatment (Table 1) were examined. These were
compared with eight healthy individuals of comparable
age and gender. The patients had a mean age of 67
(range: 51e86) years and comprised six females. The
control subjects had a mean age of 61 (53e73) years, of
which five were female. Blood samples were collected
from patients 1 d before and 14 d after the start of
sunitinib treatment. A single blood sample was collected
from the control donors. Median platelet count of RCC
patients was 243 (range: 200e526)  109/l before the
start of sunitinib treatment, which was not significantly
different from healthy controls (212  109/l; range:
167e300). Fourteen days of sunitinib treatment were
accompanied by a significant decrease in platelet count
to 144  109/l (range: 66e563, P < 0.05). Bleeding
events were reported from the start of sunitinib treat-
ment until 2 weeks after the second blood sample (i.e.
Table 1

















1 Female 69 50 234 124 Epistaxis
2 Female 86 50 296 66 No
3 Female 57 50 213 182 No
4 Male 84 50 200 128 Epistaxis/GI
bleeding
5 Male 51 50 253 104 No
6 Female 62 25 285 268 No
7 Female 72 50 526 563 Epistaxis
8 Female 58 50 230 160 Epistaxis
GI Z gastrointestinal.
a Bleeding events were reported during the first 4 weeks (Zfirst cycle)
of sunitinib treatment.
S. Sabrkhany et al. / European Journal of Cancer 66 (2016) 47e54 51during the four weeks [Z first cycle] of sunitinib treat-
ment). Bleeding complications were observed in four
patients. Three patients developed mild epistaxis, while
one patient presented with gastrointestinal bleeding
requiring blood transfusion.
We investigated the effects of sunitinib treatment of
patients on the functioning of their platelets. Confocal
microscopy of platelets from RCC patients treated with
sunitinib indicated significant sequestration of this
fluorescent compound into the cytoplasm and granular
structures (Fig. 3A). This observation confirmed that,
also in patients, platelets take up sunitinib. Before the
start of treatment, collagen- and ADP-induced aggre-
gation of platelets from RCC patients did not differ
from control (Fig. 3B,C). However, after 14 d of suni-
tinib treatment, the platelet response to collagen was
significantly reduced by 45% in the patient group
(Fig. 3B). Aggregation of patient platelets in response to
ADP was not influenced by sunitinib treatment
(Fig. 3C).
The aggregation data were confirmed by flow cyto-
metric measurements of platelet integrin aIIbb3 activa-
tion and a-granule secretion (P-selectin expression). No
differences in platelet activation were found between
healthy subjects and patients before the start of treat-
ment. After 2 weeks on sunitinib treatment, the patients’
platelets showed a diminished response with convulxin,
an agonist for the collagen receptor Glycoprotein VI
(GPVI) (Supplementary Fig. 2). Platelet activation re-
sponses to ADP or thrombin were not significantly
influenced.
In whole blood perfusion experiments over a collagen
surface, blood from healthy donors demonstrated
reproducible platelet deposition and subsequent
thrombus formation (Fig. 3D: median surface area
coverage 28%, n Z 8). Before treatment, perfusion of
patient blood resulted in an increased accumulation of
platelets on the collagen surface and the formation of
larger packed thrombi when compared to healthycontrols (Fig. 3D). Quantification of the area covered by
platelets revealed a 47% increase in thrombus formation
in patients compared to controls of similar age and
gender (Fig. 3D). Two weeks after the start of sunitinib
treatment, thrombus formation was significantly
reduced by 16% (Fig. 3D).
To detect phosphatidylserine-exposing platelets, we
poststained with fluorescently labelled annexin A5 and
observed ample procoagulant platelets on the collagen
with blood from healthy subjects (Fig. 3D). In RCC
patients before treatment, the amount of phosphati-
dylserine-exposing platelets was significantly increased
by 80% (Fig. 3D). Two weeks of sunitinib treatment
significantly diminished the area covered by platelets
exposing phosphatidylserine to the healthy control level
(Fig. 3D).4. Discussion
The present study shows that the multi-TKI sunitinib is
taken up by platelets and inhibits collagen receptor-
induced integrin activation, secretion, aggregation and
thrombus formation. Protein tyrosine kinases are
abundantly expressed in platelets and play important
roles in platelet activation and haemostasis [9]. It has
been shown that sunitinib also affects tyrosine kinases
that are expressed in platelets [10]. This may explain that
sunitinib treatment was accompanied by bleeding epi-
sodes in four of eight investigated cancer patients (Table
1), which is in agreement with reports on the use of
several other non-selective TKIs in cancer therapy
[3,11,12]. As no correlation existed between absolute
platelet count and the occurrence of bleeding (Table 1)
and the reduction in platelet count was only moderate in
RCC patients on treatment with sunitinib, it is unlikely
that the decrease in platelet count alone leads to
bleeding. The present results also demonstrate that
sunitinib reduces platelet functioning. Hence, this com-
bination of antiplatelet effects (i.e. both on platelet
count and functioning) may contribute to the higher
bleeding risk observed in patients treated with sunitinib.
In addition, endothelial dysfunction and increased
capillary leakage as induced by treatment with sunitinib
or other angiogenesis inhibitors [13] may also play a role
in the increased bleeding tendency. Paradoxically,
interfering with the integrity of the endothelial cells can
also shift the haemostatic balance in favour of throm-
bosis; treatment with sunitinib and other TKIs have also
been associated with an increase in arterial thrombo-
embolic events in RCC patients [13,14].
Sunitinib sequestration has been reported in lyso-
somes of tumour cells and endothelial cells [15]. Because
platelets are also known to incorporate substances from
plasma, like angiogenesis regulators [16] and anti-
angiogenic medication [17], it was hypothesised that
platelets take up sunitinib as well. Confocal microscopy
Fig. 3. Treatment with sunitinib inhibits collagen-induced platelet functioning in RCC patients. (A) Confocal microscopy of platelets from
a patient after 2 weeks of sunitinib treatment (sunitinib Z green). Platelet membranes were stained with anti-CD42b mAb (red). Note
localisation of sunitinib inside the platelets (right image). Bar Z 10 mm; (B-C) Blood was collected from healthy controls and RCC
patients the day before and after 2 weeks on sunitinib treatment. Washed platelets (250  109/l) were isolated, and aggregation was
induced by 1 mg/ml collagen (B) or 10 nM Me-S-ADP (C). Representative aggregation traces are shown. Arrow indicates addition of
agonist. Histograms indicate maximal amplitude of aggregation (nZ 8). (D) Whole blood was perfused over a collagen surface at 1000 s1
for 5 min, followed by buffer perfusion supplemented with FITC-annexin A5. Microscopy images show representative brightfield and
fluorescence images (Bar Z 20 mm). Histograms indicate quantification of surface area coverage (SAC) by thrombi (n Z 8) and
phosphatidylserine-exposing platelets (n Z 7). All histograms indicate medians  interquartile ranges, *P < 0.05 and **P < 0.01.
DIC Z differential interference contrast; RCC Z renal cell cancer. (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.).
S. Sabrkhany et al. / European Journal of Cancer 66 (2016) 47e5452indeed showed that platelets treated with 10 mM suni-
tinib, a dose resembling plasma concentrations in
treated patients [18], take up sunitinib within minutes
after exposure and sequester this fluorescent compound
in granules.
Aggregation experiments of control platelets showed
a selective inhibitory effect of sunitinib on collagen- and/
or ADP-induced aggregation, suggesting that sunitinib
interferes with the signalling pathways activated by
glycoprotein VI and/or P2Y12. The observed reductionof collagen-induced tyrosine phosphorylation of multi-
ple proteins implies interference of sunitinib early in the
signalling cascade used by the collagen receptor GPVI,
e.g., with tyrosine kinases in the GPVI signalosome or
with Syk as a central regulator of collagen-induced
platelet activation. This is consistent with the multi-
target nature of sunitinib as a broad-spectrum protein
TKI [2,19]. Platelets contain several tyrosine kinases
implicated in platelet functioning, mostly acting in the
collagen-induced signalling pathway [4]. The finding
S. Sabrkhany et al. / European Journal of Cancer 66 (2016) 47e54 53that aggregation of the patients’ platelets in response to
ADP was not significantly inhibited by sunitinib treat-
ment contrasts with the in vitro effect of sunitinib on
control platelets; this parallels recent findings with
ibrutinib [20,21]. The explanation for this distinction
remains unknown.
Secretion of platelet-derived angiogenesis regulatory
proteins is essential in tumour angiogenesis and tumour
growth [7]. We observed that incubation of platelets
with sunitinib resulted in a decrease of b-TG and PDGF
secretion. Alpha granules are the main location of most
angiogenesis regulatory proteins in platelets [22], sug-
gesting that reduced secretion of b-TG and PDGF re-
flects reduced release of other angiogenesis regulatory
proteins as well. Even though platelets contain both
proangiogenic and antiangiogenic factors, their overall
effect on tumour angiogenesis and growth is stimulatory
[7]. Therefore, the inhibitory effect of sunitinib on
platelet secretion suggests a new additional mechanism
by which this drug can inhibit tumour angiogenesis and
growth. This notion contributes to the idea that platelets
are important actors in cancer development and should
be taken into account, also when searching for blood-
based biomarkers [23].
The current data also show that, before starting
sunitinib treatment, platelets from metastatic RCC pa-
tients display significantly enhanced collagen-induced
thrombus formation and procoagulant activity in flow
experiments, when compared to a control group of
similar age and gender. These findings confirm the fact
that cancer patients are at increased risk for thrombosis
[24] and that metastatic cancer is associated with
increased platelet reactivity [25]. Two weeks of sunitinib
treatment significantly diminished thrombus formation
and phosphatidylserine exposure to the healthy control
level, normalising platelet functioning and reducing the
risk for thrombosis.
Our results support other studies showing platelet
inhibition by TKIs used for treatment of leukaemia.
Dasatinib and imatinib, used for treatment of chronic
myeloid leukaemia, have been demonstrated to inhibit
platelet aggregation and thrombus formation in
response to collagen and are associated with increased
bleeding as well [12,26]. Ibrutinib, given to patients with
chronic lymphocytic leukaemia, has also been linked to
the occurrence of bleeding events and has been shown to
inhibit collagen- and vWF-dependent platelet functions
[20,21,27]. In contrast to imatinib, dasatinib and ibru-
tinib, sunitinib is a multitarget TKI affecting many
protein tyrosine kinases [2,19]. Beside treatment of RCC
and of imatinib-resistant gastrointestinal and pancreatic
neuroendocrine tumours [2], the use of sunitinib for
several other solid malignancies is currently being
explored. Therefore, the present data are potentially
relevant for large patient groups.
In summary, this study demonstrates that sunitinib is
rapidly taken up by platelets and reduces collagenreceptor-induced platelet aggregation and thrombus
formation via inhibition of tyrosine phosphorylation
and a-granule secretion. In combination with its
reducing effect on platelet count, this may contribute to
the higher bleeding tendency observed in RCC patients
treated with sunitinib. Therefore, clinicians should take
ultimate care while using sunitinib in patients who pre-
viously experienced bleeding or use antiplatelet drugs. In
addition, it is suggested to take platelet effects into ac-
count in the development of angiostatic compounds.Funding
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